Barr Pharmaceuticals receives approval for generic Taxol injection

Barr Pharmaceuticals, Inc. announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Bristol-Myers Squibb Company's Taxol (paclitaxel) Injection USP, 6mg/mL, packaged in 100mg/16.7 mL and 300mg/50 mL Multiple-dose Vials.

The Company plans to launch its product shortly. Barr's U.S. generic injectable portfolio now totals seven products.

Barr's product will compete in a market that had annual sales of approximately $98 million for the twelve months ended January 2008, based on IMS sales data.